{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:14:04Z","timestamp":1791382444861,"version":"4.3.3"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Program of Introducing Talents of Discipline to Universities","award":["B20017"],"award-info":[{"award-number":["B20017"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U24A20704, 82073458, 82372934"],"award-info":[{"award-number":["U24A20704, 82073458, 82372934"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ3052"],"award-info":[{"award-number":["2024JJ3052"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Melanoma, a highly aggressive and immunogenic skin cancer, often develops resistance to immunotherapy due to the immunosuppressive tumor microenvironment (TME). Although PD-1\/PD-L1 inhibitors have significantly improved treatment outcomes, 30%-40% of patients exhibit no response or develop resistance. Mechanisms such as T-cell exhaustion within the TME limit therapeutic efficacy, necessitating the exploration of novel strategies to enhance immune responses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study evaluated the effects of Vinburnine (Vin) on melanoma cell proliferation, migration, invasion, apoptosis, and DNA damage through in vitro experiments. Transcriptomic analysis, Western blot, RT-PCR, dual-luciferase reporter assays, and ChIP experiments revealed the mechanism by which Vin regulates IL-24 via ATF3. The anti-tumor efficacy of Vin or IL-24 in combination with PD-1 monoclonal antibody, as well as their modulation of the tumor microenvironment, were validated through luciferase-mediated cytotoxicity assays and a murine melanoma model. Additionally, the correlation between IL-24 expression and patient prognosis or immunotherapy response was analyzed using public databases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This study delineates the phenotypic mechanisms by which vinburnine suppresses melanoma proliferation. Vin induces reactive oxygen species (ROS) generation, leading to DNA damage and the subsequent activation of the apoptotic cascade in melanoma cells. Additionally, vinburnine activates the P38\/MAPK\/ATF3 signaling axis, which drives the secretion of interleukin-24 (IL-24), enhancing the functionality of CD8<jats:sup>+<\/jats:sup> T cells and modulating the tumor immune microenvironment to favor antitumor immunity. Notably, the combination of vinburnine with anti-PD-1 antibody therapy produces synergistic effects, effectively addressing certain limitations of current immunotherapeutic approaches.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings underscore the therapeutic potential of vinburnine, particularly when used in combination with immune checkpoint inhibitors, as a promising strategy for melanoma treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03521-5","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T03:53:31Z","timestamp":1756266811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Vinburnine potentiates anti-PD1 immunotherapy in melanoma through IL-24 secretion via P38\/MAPK\/ATF3 signaling"],"prefix":"10.1186","volume":"44","author":[{"given":"Susi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waner","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7104-5490","authenticated-orcid":false,"given":"Cong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"18","key":"3521_CR1","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391(18):1696\u2013708.","journal-title":"N Engl J Med"},{"issue":"11","key":"3521_CR2","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.ccell.2024.10.007","volume":"42","author":"D Davar","year":"2024","unstructured":"Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, et al. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024;42(11):1898\u2013e91812.","journal-title":"Cancer Cell"},{"issue":"15","key":"3521_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600\u20139.","journal-title":"JAMA"},{"key":"3521_CR4","doi-asserted-by":"crossref","unstructured":"Bai X, Kim M, Kasumova G, Si L, Tang B, Cui C et al. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. J Immunother Cancer. 2021;9(2).","DOI":"10.1136\/jitc-2020-002092"},{"key":"3521_CR5","doi-asserted-by":"publisher","first-page":"104426","DOI":"10.1016\/j.critrevonc.2024.104426","volume":"201","author":"W Li","year":"2024","unstructured":"Li W, Gu J, Fan H, Zhang L, Guo J, Si L. Evolving cancer resistance to anti-PD-1\/PD-L1 antibodies in melanoma: comprehensive insights with future prospects. Crit Rev Oncol Hematol. 2024;201:104426.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"3521_CR6","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","volume":"32","author":"SL Topalian","year":"2014","unstructured":"Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020\u201330.","journal-title":"J Clin Oncol"},{"key":"3521_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"key":"3521_CR8","doi-asserted-by":"crossref","unstructured":"Eddy K, Chen S. Overcoming immune evasion in melanoma. Int J Mol Sci. 2020;21(23).","DOI":"10.3390\/ijms21238984"},{"issue":"1","key":"3521_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12943-024-02104-w","volume":"23","author":"Y Sun","year":"2024","unstructured":"Sun Y, Yinwang E, Wang S, Wang Z, Wang F, Xue Y, et al. Phenotypic and Spatial heterogeneity of CD8(+) tumour infiltrating lymphocytes. Mol Cancer. 2024;23(1):193.","journal-title":"Mol Cancer"},{"issue":"6","key":"3521_CR10","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch L, Baumgaertner P, Dev\u00eavre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8\u207a T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350\u201360.","journal-title":"J Clin Invest"},{"key":"3521_CR11","doi-asserted-by":"publisher","first-page":"1476904","DOI":"10.3389\/fimmu.2024.1476904","volume":"15","author":"B Zhang","year":"2024","unstructured":"Zhang B, Liu J, Mo Y, Zhang K, Huang B, Shang D. CD8(+) T cell exhaustion and its regulatory mechanisms in the tumor microenvironment: key to the success of immunotherapy. Front Immunol. 2024;15:1476904.","journal-title":"Front Immunol"},{"key":"3521_CR12","doi-asserted-by":"publisher","first-page":"122815","DOI":"10.1016\/j.biomaterials.2024.122815","volume":"314","author":"N Liu","year":"2025","unstructured":"Liu N, Yan M, Lu C, Tao Q, Wu J, Zhou Z, et al. Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1\/CCL5 mediated M1 macrophage polarization in melanoma. Biomaterials. 2025;314:122815.","journal-title":"Biomaterials"},{"key":"3521_CR13","doi-asserted-by":"crossref","unstructured":"Hanahan D, Michielin O, Pittet MJ. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. Nat Rev Cancer. 2024.","DOI":"10.1038\/s41568-024-00761-z"},{"key":"3521_CR14","unstructured":"Lu J, Giuntoli RL 2nd, Omiya R, Kobayashi H, Kennedy R, Celis E. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002;8(12):3877\u201384."},{"issue":"2","key":"3521_CR15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1073\/pnas.1814642116","volume":"116","author":"RM Santana Carrero","year":"2019","unstructured":"Santana Carrero RM, Beceren-Braun F, Rivas SC, Hegde SM, Gangadharan A, Plote D, et al. IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses. Proc Natl Acad Sci U S A. 2019;116(2):599\u2013608.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3521_CR16","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/med.21876","volume":"42","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, Vong CT, Chen F, Tan H, Zhang C, Wang N, et al. Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: helping to fight against cancer via multiple targets. Med Res Rev. 2022;42(3):1246\u201379.","journal-title":"Med Res Rev"},{"key":"3521_CR17","doi-asserted-by":"publisher","first-page":"155608","DOI":"10.1016\/j.phymed.2024.155608","volume":"129","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zeng Y, Yang W, Wang X, Jiang J. Targeting CD8(+) T cells with natural products for tumor therapy: revealing insights into the mechanisms. Phytomedicine. 2024;129:155608.","journal-title":"Phytomedicine"},{"key":"3521_CR18","doi-asserted-by":"publisher","first-page":"115346","DOI":"10.1016\/j.jpba.2023.115346","volume":"229","author":"G Shan","year":"2023","unstructured":"Shan G, Minchao K, Jizhao W, Rui Z, Guangjian Z, Jin Z, et al. Resveratrol improves the cytotoxic effect of CD8\u2009+\u2009T cells in the tumor microenvironment by regulating hmmr\/ferroptosis in lung squamous cell carcinoma. J Pharm Biomed Anal. 2023;229:115346.","journal-title":"J Pharm Biomed Anal"},{"key":"3521_CR19","doi-asserted-by":"publisher","first-page":"153758","DOI":"10.1016\/j.phymed.2021.153758","volume":"92","author":"L Liu","year":"2021","unstructured":"Liu L, Lim MA, Jung SN, Oh C, Won HR, Jin YL, et al. The effect of Curcumin on multi-level immune checkpoint Blockade and T cell dysfunction in head and neck cancer. Phytomedicine. 2021;92:153758.","journal-title":"Phytomedicine"},{"issue":"8","key":"3521_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1158\/2326-6066.CIR-19-0616","volume":"8","author":"TS Lau","year":"2020","unstructured":"Lau TS, Chan LKY, Man GCW, Wong CH, Lee JHS, Yim SF, et al. Paclitaxel induces Immunogenic cell death in ovarian cancer via TLR4\/IKK2\/SNARE-Dependent exocytosis. Cancer Immunol Res. 2020;8(8):1099\u2013111.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"3521_CR21","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41588-025-02077-6","volume":"57","author":"L Liang","year":"2025","unstructured":"Liang L, Kuang X, He Y, Zhu L, Lau P, Li X, et al. Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. Nat Genet. 2025;57(3):680\u201393.","journal-title":"Nat Genet"},{"issue":"9","key":"3521_CR22","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/s43018-023-00610-2","volume":"4","author":"R V\u00e1raljai","year":"2023","unstructured":"V\u00e1raljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, et al. Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint Inhibition in melanoma. Nat Cancer. 2023;4(9):1292\u2013308.","journal-title":"Nat Cancer"},{"issue":"1","key":"3521_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12935-021-02093-6","volume":"21","author":"X Wu","year":"2021","unstructured":"Wu X, Li J, Yan T, Ke X, Li X, Zhu Y, et al. HOXB7 acts as an oncogenic biomarker in head and neck squamous cell carcinoma. Cancer Cell Int. 2021;21(1):393.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"3521_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1186\/s12885-016-2942-5","volume":"16","author":"MA Mustufa","year":"2016","unstructured":"Mustufa MA, Ozen C, Hashmi IA, Aslam A, Baig JA, Yildiz G, et al. Synthesis and bio-molecular study of (+)-N-Acetyl-\u03b1-amino acid dehydroabietylamine derivative for the selective therapy of hepatocellular carcinoma. BMC Cancer. 2016;16(1):883.","journal-title":"BMC Cancer"},{"issue":"2","key":"3521_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11684-022-0935-0","volume":"17","author":"S Zhu","year":"2023","unstructured":"Zhu S, Zhang X, Guo Y, Tang L, Zhou Z, Chen X, et al. NETO2 promotes melanoma progression via activation of the Ca(2+)\/CaMKII signaling pathway. Front Med. 2023;17(2):263\u201374.","journal-title":"Front Med"},{"issue":"1","key":"3521_CR26","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s13046-022-02427-w","volume":"41","author":"X Zhang","year":"2022","unstructured":"Zhang X, Guo Y, Xiao T, Li J, Guo A, Lei L, et al. CD147 mediates epidermal malignant transformation through the RSK2\/AP-1 pathway. J Exp Clin Cancer Res. 2022;41(1):246.","journal-title":"J Exp Clin Cancer Res"},{"key":"3521_CR27","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","volume":"25","author":"US Srinivas","year":"2019","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD. ROS and the DNA damage response in cancer. Redox Biol. 2019;25:101084.","journal-title":"Redox Biol"},{"key":"3521_CR28","doi-asserted-by":"crossref","unstructured":"Zhao Y, Ye X, Xiong Z, Ihsan A, Ares I, Mart\u00ednez M et al. Cancer Metabolism: The Role of ROS in DNA Damage and Induction of Apoptosis in Cancer Cells. Metabolites. 2023;13(7).","DOI":"10.3390\/metabo13070796"},{"issue":"2","key":"3521_CR29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1042\/BJ20061081","volume":"401","author":"D Lu","year":"2007","unstructured":"Lu D, Chen J, Hai T. The regulation of ATF3 gene expression by mitogen-activated protein kinases. Biochem J. 2007;401(2):559\u201367.","journal-title":"Biochem J"},{"issue":"3","key":"3521_CR30","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"DJ Newman","year":"2020","unstructured":"Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019. J Nat Prod. 2020;83(3):770\u2013803.","journal-title":"J Nat Prod"},{"issue":"21","key":"3521_CR31","doi-asserted-by":"publisher","first-page":"6806","DOI":"10.1021\/bi953037i","volume":"35","author":"S Lobert","year":"1996","unstructured":"Lobert S, Vulevic B, Correia JJ. Interaction of Vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and Vinorelbine. Biochemistry. 1996;35(21):6806\u201314.","journal-title":"Biochemistry"},{"issue":"2","key":"3521_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0163-7258(91)90081-V","volume":"51","author":"RH Himes","year":"1991","unstructured":"Himes RH. Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther. 1991;51(2):257\u201367.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"3521_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1200\/JCO.21.01281","volume":"41","author":"LM Fornecker","year":"2023","unstructured":"Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, et al. Brentuximab Vedotin plus AVD for First-Line treatment of Early-Stage unfavorable hodgkin lymphoma (BREACH): A multicenter, Open-Label, randomized, phase II trial. J Clin Oncol. 2023;41(2):327\u201335.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3521_CR34","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41416-021-01420-y","volume":"125","author":"X Xu","year":"2021","unstructured":"Xu X, Wang Y, Bryce NS, Tang K, Meagher NS, Kang EY, et al. Targeting the actin\/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. Br J Cancer. 2021;125(2):265\u201376.","journal-title":"Br J Cancer"},{"issue":"25","key":"3521_CR35","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1056\/NEJMoa043623","volume":"352","author":"T Winton","year":"2005","unstructured":"Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589\u201397.","journal-title":"N Engl J Med"},{"issue":"5","key":"3521_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1055\/s-2007-1017276","volume":"19","author":"W Jansen","year":"1986","unstructured":"Jansen W, O\u2019Connolly M, Lehmann E, Mayer M. Experimental clinical studies on the effect of eburnamonine in cerebrovascular disorders. Pharmacopsychiatry. 1986;19(5):389\u201394.","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"3521_CR37","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/med.20043","volume":"25","author":"A Vas","year":"2005","unstructured":"Vas A, Guly\u00e1s B. Eburnamine derivatives and the brain. Med Res Rev. 2005;25(6):737\u201357.","journal-title":"Med Res Rev"},{"issue":"2","key":"3521_CR38","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00280-015-2924-3","volume":"77","author":"TE Fandy","year":"2016","unstructured":"Fandy TE, Abdallah I, Khayat M, Colby DA, Hassan HE. In vitro characterization of transport and metabolism of the alkaloids: vincamine, vinpocetine and eburnamonine. Cancer Chemother Pharmacol. 2016;77(2):259\u201367.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3521_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12920-024-01870-2","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, Yao Y, Zhang Y, Xu C, Yang T, Qu M, et al. Identification of prognostic stemness-related genes in kidney renal papillary cell carcinoma. BMC Med Genomics. 2024;17(1):121.","journal-title":"BMC Med Genomics"},{"issue":"1","key":"3521_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12943-017-0667-y","volume":"16","author":"G Cesi","year":"2017","unstructured":"Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. Mol Cancer. 2017;16(1):102.","journal-title":"Mol Cancer"},{"issue":"7","key":"3521_CR41","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-22-1826","volume":"83","author":"OM Eichhoff","year":"2023","unstructured":"Eichhoff OM, Stoffel CI, K\u00e4sler J, Briker L, Turko P, Karsai G, et al. ROS induction targets persister cancer cells with low metabolic activity in NRAS-Mutated melanoma. Cancer Res. 2023;83(7):1128\u201346.","journal-title":"Cancer Res"},{"issue":"10","key":"3521_CR42","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1016\/j.cub.2014.03.034","volume":"24","author":"M Schieber","year":"2014","unstructured":"Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453\u201362.","journal-title":"Curr Biol"},{"issue":"1","key":"3521_CR43","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2015.2","volume":"16","author":"WP Roos","year":"2016","unstructured":"Roos WP, Thomas AD, Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer. 2016;16(1):20\u201333.","journal-title":"Nat Rev Cancer"},{"key":"3521_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1476-4598-11-25","volume":"11","author":"A Buqu\u00e9","year":"2012","unstructured":"Buqu\u00e9 A, Muhialdin J, Mu\u00f1oz A, Calvo B, Carrera S, Aresti U, et al. Molecular mechanism implicated in Pemetrexed-induced apoptosis in human melanoma cells. Mol Cancer. 2012;11:25.","journal-title":"Mol Cancer"},{"key":"3521_CR45","doi-asserted-by":"crossref","unstructured":"Whitaker RH, Cook JG. Stress relief techniques: p38 MAPK determines the balance of cell cycle and apoptosis pathways. Biomolecules. 2021;11(10).","DOI":"10.3390\/biom11101444"},{"issue":"5","key":"3521_CR46","doi-asserted-by":"publisher","first-page":"428","DOI":"10.7150\/ijbs.5.428","volume":"5","author":"CD Wood","year":"2009","unstructured":"Wood CD, Thornton TM, Sabio G, Davis RA, Rincon M. Nuclear localization of p38 MAPK in response to DNA damage. Int J Biol Sci. 2009;5(5):428\u201337.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"3521_CR47","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41419-023-06182-4","volume":"14","author":"Q Wu","year":"2023","unstructured":"Wu Q, Liang Z, Jiang J, Feng X, Liu J, Zhang Z, et al. Macrophages originated IL-33\/ST2 inhibits ferroptosis in endometriosis via the ATF3\/SLC7A11 axis. Cell Death Dis. 2023;14(10):668.","journal-title":"Cell Death Dis"},{"key":"3521_CR48","doi-asserted-by":"crossref","unstructured":"Shi Q, Hu B, Yang C, Zhao L, Wu J, Qi N. ATF3 promotes Arsenic-Induced apoptosis and oppositely regulates DR5 and Bcl-xL expression in human bronchial epithelial cells. Int J Mol Sci. 2021;22(8).","DOI":"10.3390\/ijms22084223"},{"key":"3521_CR49","doi-asserted-by":"crossref","unstructured":"Liu S, Li Z, Lan S, Hao H, Baz AA, Yan X et al. The dual roles of activating transcription factor 3 (ATF3) in inflammation, apoptosis, ferroptosis, and pathogen infection responses. Int J Mol Sci. 2024;25(2).","DOI":"10.3390\/ijms25020824"},{"key":"3521_CR50","doi-asserted-by":"publisher","first-page":"152890","DOI":"10.1016\/j.tox.2021.152890","volume":"460","author":"Q Shi","year":"2021","unstructured":"Shi Q, Hu B, Yang C, Deng S, Cheng X, Wu J, et al. ATF3 inhibits arsenic-induced malignant transformation of human bronchial epithelial cells by attenuating inflammation. Toxicology. 2021;460:152890.","journal-title":"Toxicology"},{"issue":"12","key":"3521_CR51","first-page":"2477","volume":"11","author":"H Jiang","year":"1995","unstructured":"Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 1995;11(12):2477\u201386.","journal-title":"Oncogene"},{"issue":"17","key":"3521_CR52","doi-asserted-by":"publisher","first-page":"9160","DOI":"10.1073\/pnas.93.17.9160","volume":"93","author":"H Jiang","year":"1996","unstructured":"Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci U S A. 1996;93(17):9160\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3521_CR53","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41401-023-01165-9","volume":"45","author":"JX Xiong","year":"2024","unstructured":"Xiong JX, Li YT, Tan XY, Chen T, Liu BH, Fu L. Targeting PRSS23 with Tipranavir induces gastric cancer stem cell apoptosis and inhibits growth of gastric cancer via the MKK3\/p38 MAPK-IL24 pathway. Acta Pharmacol Sin. 2024;45(2):405\u201321.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"3521_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12885-023-11021-y","volume":"23","author":"SM Babazadeh","year":"2023","unstructured":"Babazadeh SM, Zolfaghari MR, Zargar M, Baesi K, Hosseini SY, Ghaemi A. Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy. BMC Cancer. 2023;23(1):519.","journal-title":"BMC Cancer"},{"key":"3521_CR55","doi-asserted-by":"publisher","first-page":"112305","DOI":"10.1016\/j.intimp.2024.112305","volume":"136","author":"Q Wu","year":"2024","unstructured":"Wu Q, Jin Y, Li S, Guo X, Sun W, Liu J, et al. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Int Immunopharmacol. 2024;136:112305.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"3521_CR56","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/1878-0261.13607","volume":"18","author":"A Roy","year":"2024","unstructured":"Roy A, Chakraborty AR, DePamphilis ML. PIKFYVE inhibitors trigger interleukin-24-dependent cell death of autophagy-dependent melanoma. Mol Oncol. 2024;18(4):988\u20131011.","journal-title":"Mol Oncol"},{"issue":"12","key":"3521_CR57","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1007\/s00449-022-02801-0","volume":"45","author":"J Hua","year":"2022","unstructured":"Hua J, Xu H, Zhang Y, Ge J, Liu M, Wang Y, et al. Enhancement of Recombinant human IL-24 (rhIL-24) protein production from site-specific integrated engineered CHO cells by sodium butyrate treatment. Bioprocess Biosyst Eng. 2022;45(12):1979\u201391.","journal-title":"Bioprocess Biosyst Eng"},{"issue":"2","key":"3521_CR58","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pharmthera.2010.08.001","volume":"128","author":"P Dent","year":"2010","unstructured":"Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, et al. The development of MDA-7\/IL-24 as a cancer therapeutic. Pharmacol Ther. 2010;128(2):375\u201384.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"3521_CR59","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","volume":"44","author":"JH Esensten","year":"2016","unstructured":"Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44(5):973\u201388.","journal-title":"Immunity"},{"issue":"8","key":"3521_CR60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrc3565","volume":"13","author":"MH Kershaw","year":"2013","unstructured":"Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013;13(8):525\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"3521_CR61","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451\u20138.","journal-title":"J Immunol"},{"issue":"67","key":"3521_CR62","doi-asserted-by":"publisher","first-page":"eabi6899","DOI":"10.1126\/sciimmunol.abi6899","volume":"7","author":"D Xue","year":"2022","unstructured":"Xue D, Moon B, Liao J, Guo J, Zou Z, Han Y, et al. A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Sci Immunol. 2022;7(67):eabi6899.","journal-title":"Sci Immunol"},{"issue":"7817","key":"3521_CR63","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE, et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature. 2020;583(7817):609\u201314.","journal-title":"Nature"},{"issue":"9","key":"3521_CR64","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1158\/0008-5472.CAN-20-2604","volume":"81","author":"Z Liu","year":"2021","unstructured":"Liu Z, Guo C, Das SK, Yu X, Pradhan AK, Li X, et al. Engineering T cells to express tumoricidal MDA-7\/IL24 enhances cancer immunotherapy. Cancer Res. 2021;81(9):2429\u201341.","journal-title":"Cancer Res"},{"issue":"9","key":"3521_CR65","doi-asserted-by":"publisher","first-page":"107531","DOI":"10.1016\/j.isci.2023.107531","volume":"26","author":"J Chen","year":"2023","unstructured":"Chen J, Zhang Y, Zhang H, Zhang M, Dong H, Qin T, et al. IL-24 is the key effector of Th9 cell-mediated tumor immunotherapy. iScience. 2023;26(9):107531.","journal-title":"iScience"},{"issue":"9","key":"3521_CR66","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.1074\/jbc.M106043200","volume":"277","author":"M Wang","year":"2002","unstructured":"Wang M, Tan Z, Zhang R, Kotenko SV, Liang P. Interleukin 24 (MDA-7\/MOB-5) signals through two heterodimeric receptors, IL-22R1\/IL-20R2 and IL-20R1\/IL-20R2. J Biol Chem. 2002;277(9):7341\u20137.","journal-title":"J Biol Chem"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03521-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03521-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03521-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:19:45Z","timestamp":1757441985000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03521-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3521"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03521-5","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments involving the use of animals were approved by the Ethics Committee of Xiangya Hospital, Central South University. The use of human blood samples was approved by the Ethics Committee of Xiangya Hospital, Central South University. Informed consent was obtained from all patients. The ethics project approval number is 20230006.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final version of the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}